Compare ArcelorMittal SA (MT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs TG Therapeutics Inc — how do they compare? ArcelorMittal SA trades at $74.09 (market cap $55.88B), while TG Therapeutics Inc trades at $49.91 (market cap $7.64B). The key difference: ArcelorMittal SA is far larger — about 7.3× TG Therapeutics Inc's market cap, and ArcelorMittal SA pays a 0.81% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MT | TGTX | |
|---|---|---|
Market Cap | $55.88B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $75.35 | $59.06 |
52-Week Low | $32.44 | $26.94 |
Enterprise Value | $65.45B | $7.84B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $73.90, up 0.83% with bullish technical signals and strong institutional support. The stock shows improving fundamentals with Q2 2026 revenue growth despite an earnings miss, while maintaining stable dividends. Recent news highlights strategic partnerships and European business recovery prospects.
Outlook remains cautiously optimistic with 50% analyst buy ratings, though risks include cyclical steel demand and margin pressures. The current P/E of 30.97 appears elevated relative to historical norms, requiring sustained earnings growth to justify valuation.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
